Novoseven® (recombinant factor vila) in central nervous system bleeds

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 131-134

  Rice, K M ^a   Savidge, G F ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Haemophilia; Inhibitors; Intracranial haemorrhage; Recombinant factor VIla

Indexed keywords

BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL TRIAL; HEMOPHILIA A; HUMAN; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; BRAIN HEMORRHAGE; CONFERENCE PAPER; HEMOPHILIA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; FACTOR VIIA; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0029960058     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217254     Document Type: Article

References (13)

1. Hyster EM. Gill FM. Blatt PM. Hil-gartncr MW. Ballard JO. Kinney TR, Hemophilia Study Group: Central nervous system bleeding in hemophiliacs. Blood 1978;51:1179-1188.
2. Kerr CB: Intracranial haemorrhage in hemophilia. J Neurol Neurosurg Psychiatry 1964:27:166-173.
3. Silverstein A: Intracranial bleeding in hemophilia. Arch Neurol 1960:3: 141-157.
4. Andes WA, Wulf TK. Smith WB: Head trauma in hemophilia. A prospective study. Arch Intern Med 1984:144:1981-1983.
5. Briet E. Rosendaal FR, Kreuz W, Rasi V, Pcerlinck K. Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI, Pabinger I: High titre inhibitors in severe haemophilia A. A meta-analysis based on eight longterm follow-up studies concerning inhibitors associated with crude or intermediate purity FVIII products. Thromb Hacmost 1994:72:162-164.
6. Brcttler DB. Forsbcrg AD, Levine PH, Aledort LM, Hilgartncr MW, Kasper CK. Lusher JM, McMillan C. Roberts H, Cooperating Investigators: The use of porcine factor VIII concentrate (Hyatc:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicentre US experience. Arch Intern Med 1989;149:1381-1385.
7. Hilgartncr MW. Knatterud GL. FFIBA Study Group: The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983:61:36-40.
8. Hilgartner M, Aledort L, Andes A, Gill J. members of the FEIBA Study Group: Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990:30:626-630.
9. Fukui H, Fujimura Y. Taahashi Y. Mikami S. Yoshioka A: Laboratory' evidence of DIC under FEIBA treatment of a hemophilic patier.t with intracranial bleeding and high litre factor VIII inhibitor. Thromb Res 1981:22:177-184.
10. Dalsgaard-Niclscn J: Successful treatment with FEIBA of a spontaneous intracranial bleeding in a hemophiliac patient with factor VIII inhibitor. 16th International Congress of the World Federation of Haemophilia, Rio de Janeiro. 1984.
11. Hcdner U. Glazcr S. Falclt J: Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Trans Med Rev 1993;7:78-83.
12. Schmidt ML. Gamerman S. Smith HE. Scott JP. DiMcchclc DM: Recombinant activated factor VII (rFVlIa) therapy for intracranial haemorrhage in hemophilia A patients with inhibitors. Am J Hcnta-tol 1994:47:36-40.
13. Majuntdar G. Savidge GF: Recombinant factor Vila for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors. Blood Coagul Fibrinolysis 1993;4:1031-1033.